Aims There has been considerable change in the management of type 2 diabetes over the previous decade with the introduction of several novel anti-hyperglycaemic agents and drug preparations. Here we investigated temporal changes in glycaemic control and use of anti-hyperglycaemic therapies in females and males with type 2 diabetes between 2013 to 2019. Methods Data from adult patients with type 2 diabetes (n=11,930; 44.9% females, mean (SD) age of 63.0 (12.9) years) were analysed from the 2013 to 2019 biennial cross-sectional Australian National Diabetes Audits (ANDA). Results Mean HbA1c remained similar throughout the years examined and between sexes (between 7.8% – 8.3%, 62 – 67 mmol/mol; p >0.05). The number of anti-hyperglycaemic agents used by both sexes increased between 2013 to 2019 (p <0.001) with more agents used by males (p = 0.014). Between 2013 and 2019, there were increasing proportions of both sexes using DPP-4 inhibitors (females: 11.7% to 25.7%, p = 0.045 males: 11.6% to 29.5%, p = 0.036) and GLP-1-agonists (females: 5.9% to 15.3%; males: 4.9% to 11.1%, p = 0.043 for both). SGLT2 inhibitors were not available in 2013, however their use increased substantially between 2015 and 2019 in both females (4.9% to 26.3%, p = 0.013) and males (4.7% to 32.2, p = 0.019). Conclusions Between 2013 and 2019, mean HbA1c levels remained unchanged despite a concurrent increase in the number of anti-hyperglycaemic medications used. Overall, there was a trend towards preferencing newer agents with some differences in treatment regimens relating to sex and renal function.